ArticleBMC medical imaging2026
Diagnosing breast masses in BI-RADS 4: construction and interpretation of an intralesional and perilesional radiomics nomogram based on digital breast tomosynthesis.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo evaluate the diagnostic performance of a digital breast tomosynthesis (DBT)-based, interpretable radiomics nomogram for differentiating between benign and malignant Breast Imaging Reporting and Data System (BI-RADS) category 4 masses.
methodsThis retrospective study enrolled 312 patients with BI-RADS 4 lesions assessed via DBT. Radiomics features were extracted from intralesional and perilesional regions of interest (ROIs), and used to construct three models: Radscore_IL, Radscore_PL, and Radscore_Combine. Univariate and multivariate logistic regression analyses identified independent predictors, which were integrated into clinical and nomogram models. Model performance and interpretability were assessed using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA), and Shapley Additive Explanations (SHAP) values.
resultsAmong the three radiomics models, Radscore_Combine demonstrated superior performance, with area under the curve (AUC) values of 0.935 (training) and 0.888 (validation). Age and BI-RADS 4 subclassification emerged as independent clinical predictors and were included in the clinical model. The final nomogram, incorporating Radscore_Combine, age, and BI-RADS 4 subclassification, achieved AUCs of 0.960 and 0.942 in the training and validation datases, respectively. DCA confirmed significant clinical utility of the nomogram. SHAP analysis enhanced interpretability by illustrating individual feature contributions to model predictions.
conclusionsThe DBT-based radiomics nomogram offers high diagnostic accuracy and good interpretability, making it a valuable tool for differentiating benign from malignant BI-RADS 4 masses. RELEVANCE STATEMENT: This DBT-based radiomics nomogram accurately differentiates benign and malignant BI-RADS 4 breast lesions, supporting clinical decision-making to optimize management of these ambiguous findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.